KIT L576P
|
Advanced Solid Tumor
|
sensitive
|
Axitinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Inlyta (axitinib) inhibited KIT phosphorylation and proliferation of transformed cells expressing KIT L576P in culture (PMID: 31205508).
|
31205508
|
KIT V559G
|
Advanced Solid Tumor
|
sensitive
|
Axitinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Inlyta (axitinib) inhibited KIT phosphorylation and proliferation of transformed cells expressing KIT V559G in culture (PMID: 31205508).
|
31205508
|
KIT V559D KIT V654A
|
Advanced Solid Tumor
|
sensitive
|
Sunitinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Sutent (sunitinib) inhibited proliferation of transformed cells expressing KIT V654A and KIT V559D in culture (PMID: 31205508).
|
31205508
|
KIT V559D
|
Advanced Solid Tumor
|
sensitive
|
Axitinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Inlyta (axitinib) inhibited KIT phosphorylation and proliferation of transformed cells expressing KIT V559D in culture (PMID: 31205508).
|
31205508
|
KIT V559A
|
Advanced Solid Tumor
|
sensitive
|
Axitinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Inlyta (axitinib) inhibited KIT phosphorylation and proliferation of transformed cells expressing KIT V559A in culture (PMID: 31205508).
|
31205508
|
KIT K642E
|
gastrointestinal stromal tumor
|
sensitive
|
Axitinib
|
Preclinical - Patient cell culture |
Actionable |
In a preclinical study, Inlyta (axitinib) inhibited phosphorylation of KIT and downstream signaling, reduced proliferation, and induced cell-cycle arrest in a cultured gastrointestinal stromal tumor (GIST) cell line harboring KIT K642E, and inhibited proliferation of primary GIST cells harboring KIT K642E in culture (PMID: 31205508).
|
31205508
|
KIT V559D
|
gastrointestinal stromal tumor
|
sensitive
|
Axitinib
|
Preclinical - Patient cell culture |
Actionable |
In a preclinical study, Inlyta (axitinib) inhibited proliferation of gastrointestinal stromal tumor patient-derived primary cells harboring KIT V559D in culture (PMID: 31205508).
|
31205508
|
KIT V654A
|
Advanced Solid Tumor
|
sensitive
|
Sunitinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Sutent (sunitinib) inhibited proliferation of transformed cells expressing KIT V654A in culture (PMID: 31205508).
|
31205508
|
KIT V560_Y578del
|
gastrointestinal stromal tumor
|
sensitive
|
Sunitinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Sutent (sunitinib) inhibited proliferation of a gastrointestinal stromal tumor cell line harboring KIT V560_Y578del in culture (PMID: 31205508).
|
31205508
|
KIT K642E
|
gastrointestinal stromal tumor
|
sensitive
|
Sunitinib
|
Preclinical - Patient cell culture |
Actionable |
In a preclinical study, Sutent (sunitinib) inhibited proliferation of a gastrointestinal stromal tumor (GIST) cell line and primary GIST patient-derived cells harboring KIT K642E in culture (PMID: 31205508).
|
31205508
|
KIT T670I
|
Advanced Solid Tumor
|
sensitive
|
Axitinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Inlyta (axitinib) inhibited KIT phosphorylation and proliferation of transformed cells expressing KIT T670I in culture, however, with decreased potency compared to its potency against other KIT variants (PMID: 31205508).
|
31205508
|
KIT V559D KIT T670I
|
Advanced Solid Tumor
|
sensitive
|
Sunitinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Sutent (sunitinib) inhibited proliferation of transformed cells expressing KIT T670I and KIT V559D in culture (PMID: 31205508).
|
31205508
|
KIT V560_Y578del KIT T670I
|
gastrointestinal stromal tumor
|
sensitive
|
Axitinib
|
Preclinical - Cell line xenograft |
Actionable |
In a preclinical study, Inlyta (axitinib) inhibited KIT phosphorylation and downstream signaling, reduced proliferation, and induced cell-cycle arrest in a gastrointestinal stromal tumor cell line harboring KIT V560_Y578del and KIT T670I in culture, and inhibited tumor growth in xenograft models (PMID: 31205508).
|
31205508
|
KIT V560_Y578del KIT T670I
|
gastrointestinal stromal tumor
|
sensitive
|
Sunitinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Sutent (sunitinib) inhibited proliferation of a gastrointestinal stromal tumor cell line harboring KIT V560_Y578del and KIT T670I in culture (PMID: 31205508).
|
31205508
|
KIT V559D KIT V654A
|
Advanced Solid Tumor
|
sensitive
|
Axitinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Inlyta (axitinib) inhibited KIT phosphorylation and proliferation of transformed cells expressing KIT V654A and KIT V559D in culture (PMID: 31205508).
|
31205508
|
KIT A829P
|
Advanced Solid Tumor
|
sensitive
|
Axitinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Inlyta (axitinib) inhibited KIT phosphorylation and proliferation of transformed cells expressing KIT A829P in culture, however, with decreased potency compared to its potency against other KIT variants (PMID: 31205508).
|
31205508
|
KIT T670I
|
Advanced Solid Tumor
|
sensitive
|
Sunitinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Sutent (sunitinib) inhibited proliferation of transformed cells expressing KIT T670I in culture (PMID: 31205508).
|
31205508
|
KIT V560_Y578del
|
gastrointestinal stromal tumor
|
sensitive
|
Axitinib
|
Preclinical - Cell line xenograft |
Actionable |
In a preclinical study, Inlyta (axitinib) inhibited KIT phosphorylation and downstream signaling, reduced proliferation and induced cell-cycle arrest in a gastrointestinal stromal tumor cell line harboring KIT V560_Y578del in culture, and inhibited tumor growth in xenograft models (PMID: 31205508).
|
31205508
|
KIT V654A
|
Advanced Solid Tumor
|
sensitive
|
Axitinib
|
Preclinical - Cell line xenograft |
Actionable |
In a preclinical study, Inlyta (axitinib) inhibited KIT phosphorylation and proliferation of transformed cells expressing KIT V654A in culture, and inhibited tumor growth in xenograft models (PMID: 31205508).
|
31205508
|